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Abstract 36 
Oral administration is the most commonly used drug delivery route for the majority of 37 
conditions. Given its advantages over other routes, such as convenience and cost, 38 
its use is increasing every year despite the major advances in drug delivery. 39 
Nevertheless, oral formulations are limited and challenged by physicochemical 40 
barriers and highly variable residence times. Gastric retention is a strategy that can 41 
overcome the highly variable gastric residence time by designing formulations that 42 
remain in the stomach longer than would otherwise be expected. This is especially 43 
beneficial for drugs that have an absorption window in the stomach and proximal 44 
intestine. Various techniques are discussed and include gas-generating tablets, 45 
floating microspheres, hydrodynamically balanced systems, bioadhesive particles, 46 
rafts and modified shape systems. Microspheres having the advantages of being 47 
multi-unit are further discussed with regard to their production methods and 48 
characterisation. Further, a summary of microsphere studies is presented that looks 49 
at methods used and key results.  50 
 51 
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1.0 Introduction 64 
Despite the numerous innovations in drug delivery and promising alternative routes, 65 
orally administered forms comprise more than half the drug delivery market [1] 66 
Gabor et al., 2010). Oral drug administration remains the preferred route in most 67 
clinical applications for the treatment of acute and chronic conditions [2]. It is 68 
estimated that over 90% of all medicine usage is oral and the share is increasing at 69 
10% per year [1]. Amongst the various oral delivery options such as liquids and 70 
semisolid formulations, tablets are the preferred choice given their advantages. Oral 71 
formulations are easy to self-administer. They are pain free, convenient, can 72 
accommodate a wide number of drugs, stable, easy to carry, inexpensive to 73 
manufacture and most importantly do not discourage patient compliance [1, 3. In 74 
addition, the healthcare system takes advantage of this easy and cost effective 75 
delivery especially as health care costs increase and the elderly population grows. It 76 
therefore seems like oral dosage forms are the ideal forms of therapy. However, the 77 
oral route is also one of the most challenging considering the biopharmaceutical 78 
issues such as physiochemical drug characteristics and gut physiological conditions 79 
[1].  80 
The oral route of administration comes with important limitations. Gastric physiology 81 
presents many challenges with changing environments and barriers to absorption. 82 
Therefore, it is important to consider drug solubility, permeability, lipophilicity, 83 
crystalline form, size, charge and pKa in oral formulations because they may affect 84 
drug absorption, bioavailability and therapeutic effectiveness. Physiological 85 
considerations include regional pH, absorption area, enzyme degradation, residence 86 
time and presence of microorganisms [1]. In the stomach, the two most important 87 
parameters affecting the fate of the drug are the pH and residence time [4]. Longer 88 
gastric residence time allows greater and more reliable drug absorption, however, it 89 
is highly variable and despite excellent dosage form in vitro release profiles, drug 90 
absorption is highly variable and in many cases unsatisfactory [5]. In addition, this 91 
variability exists in the same individual at different times and between individuals 92 
leading to less predictable therapeutic outcomes. Various strategies have been 93 
researched to overcome these challenges, such as using sustained release 94 
formulations, pH responsive formulations, osmotic delivery devices, enzyme 95 
mediated release, prodrugs, antigen targeting to Meyer cells and use of absorption 96 
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and permeation enhancers [1]. However, all these strategies are still limited by 97 
gastric variability, which is an important determinant of bioavailability. 98 
Gastroretentive strategies are designed to control dosage form residence time 99 
therefore leading to enhanced, prolonged and predictable drug blood levels.  100 
Gastroretentive formulations are very useful for drugs that are aimed at the stomach, 101 
drugs with poor solubility such as weakly basic drugs that do not dissolve well 102 
enough in basic environments, drugs that are unstable in the colon or drugs that 103 
have a narrow absorption window and drugs that are primarily absorbed from the 104 
stomach [5]. The concept of absorption window is relevant to compounds that have 105 
variable absorption in different regions in the gastrointestinal tract ([2]. For example, 106 
polar compounds are better absorbed from the upper gastrointestinal tract and large 107 
intestinal absorption is very poor. Therefore, their bioavailability is limited by 108 
absorption site. This is the case for many drugs, especially those in classes II to IV of 109 
the biopharmaceutical classification scheme. It is difficult and almost impossible to 110 
formulate modified release formulations for such substances and therefore 111 
absorption window targeting is a useful strategy. Other reasons that create an 112 
absorption window are differential drug solubility and stability due to pH or enzymatic 113 
degradation [2].  Figure 1 illustrates the concept.  114 
Formulation residence time in the gastrointestinal tract determines how long the 115 
formulation will be in contact with its absorption window. In humans, gastric 116 
residence is very variable and mainly affected by the size of the objects inside and 117 
the feeding state in the stomach. This can range from 2 to 4 hours for a meal. On the 118 
other hand, transit in the intestine is more constant and around three hours.  Transit 119 
through the colon is longer and can be 20 hours or more [2]. This therefore means 120 
that drugs that are mainly absorbed from the stomach or proximal small intestine will 121 
have a short contact time with the absorption window.  Consequently, the 122 
bioavailability will be limited and will also be variable. A number of important drugs, 123 
such as those in Table 1, that are absorbed from the proximal intestine have low 124 
bioavailability after oral dosing due to this. Sustained or prolonged release 125 
formulations for such drugs have limited benefit because absorption is low in the 126 
colon. Gastroretentive strategies overcome the short and variable contact time in two 127 
ways: (1) retain drug formulation longer and (2) hold the drug formulation above the 128 
absorption window [2].  129 
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In effect, gastro-retentive strategies improve oral bioavailability and optimize drug 130 
plasma levels leading to enhanced and predictable therapeutic outcomes. 131 
Gastroretentive formulations also have fewer doses per day leading to dramatically 132 
improved patient compliance [6].  133 
2.0 Gastric physiology  134 
The stomach is a J shaped enlargement of the gastrointestinal tract and connects 135 
the oesophagus to the first part of the small intestine. Meals can be ingested faster 136 
than nutrients can be absorbed through the intestines and the stomach serves as a 137 
mixing chamber that liquefies food and holds churned food material for controlled 138 
feeding in to the intestine. Digestion of proteins and triglycerides begins, digestion of 139 
starch continues and some substances are absorbed. The stomach is divided in to 140 
four main regions: the cardia, fundus, body and pylorus. These are shown in figure 2. 141 
 An empty stomach is about the size of a big sausage with a residual volume of 25 to 142 
50ml, but it is the most distensible part of the gastrointestinal tract and can 143 
accommodate large amounts of food. Gastric volume is important for dosage form 144 
dissolution. At birth the stomach capacity is 30 ml, at puberty it is 1L and 1.5 to 2L in 145 
adults. The fasting stomach pH is between 1.2 to 2.0 and 3 to 6.5 when fed [3]. This 146 
is because food buffers, dilutes and neutralises gastric acid and causes its increase 147 
pH. Gastric pH affects the absorption of drugs, for example, basic drugs will be more 148 
likely to dissolve in the fed condition than the fasted condition. After a meal is 149 
finished, the stomach pH rapidly increases to 5 and then gradually reduces to the 150 
fasting condition levels over a few hours [3].  151 
The gastric system is in constant motility, which is in two modes, the inter-digestive 152 
or migrating motor complex and the digestive motility pattern. Digestion begins a few 153 
minutes after food enters the stomach with peristaltic mixing waves. Few waves are 154 
seen in the fundus, which mostly has a storage function. These waves mix the food 155 
with gastric secretions and break it down to chyme. As digestion continues, more 156 
vigorous waves starting from the body and intensifying at the pylorus are produced. 157 
Most chyme is forced backward and the next wave pushes the chyme forward again 158 
and small amount may go past the pylorus. These movements are responsible for 159 
most mixing in the stomach. Stomach contents must be 1 -2 mm to pass through to 160 
the duodenum, the first part of the intestine. Food that has been held in the fundus 161 
and has not yet mixed with gastric content may be brought down, which may be held 162 
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in the fundus for an hour. The control of these movements and of gastric secretions 163 
is via neuronal and hormonal mechanisms. The events that occur in the stomach 164 
occur in three overlapping phases: the cephalic, gastric and intestinal phase [7]. 165 
Inter-digestive motility is dominant in the fasted state and its primary role is to clean 166 
up any residual content remaining in the stomach. The motility is cyclical and called 167 
the migrating motor complex (MMC) and leads to gastric emptying. MMC cycles, 168 
which last for 2 to 3 hours are separated by periods of inactivity. The cycle is divided 169 
into four phases summarised in table 2 and represented diagrammatically in figure 3. 170 
When a meal is eaten, the pattern of contractions changes to that of the fed state. 171 
The contractions in the fed state resemble phase II contractions in the MMC. 172 
Gastric motility is highly variable and affected by various factors, such as age, 173 
posture, gender and type of meal consumed. These are summarised in Table 3. 174 
Time taken for a dosage form to traverse the stomach is the ‘gastric emptying rate’, 175 
which is highly variable and dependent on many factors, such as the dosage form 176 
itself and stomach fed or fasting condition. Usually, gastric residence is 5 minutes to 177 
2 hours and large single unit dosage forms have been shown to remain for 12 hours 178 
or longer [3]. For a formulation to be gastroretentive, it must be able to resist the 179 
forces of the IMMC phase for a considerable period of time, especially the phase III 180 
forceful contractions. In addition, the IMMC phase which is occurring when the 181 
dosage form is taken affects its residence time [8].  182 
In the fed state, drug residence time is affected by food residence time. This, in turn, 183 
is affected by the type and amount of food consumed. Solids and larger food 184 
particles spend longer in the stomach than liquids or small food particles [8]. The 185 
size of a gastroretentive dosage form is also important. The human pyloric sphincter 186 
is 12 ± 7 mm in diameter and is open in the fasting state. The first mouthful can 187 
therefore pass straight to the duodenum, after which the sphincter closes. Particles 188 
with a diameter less than 7mm are effectively evacuated, whereas a diameter of 189 
15mm or greater is usually retained longer, especially during the fasting state. 190 
Indigestible solids larger than the pyloric sphincter are propelled back in to the 191 
stomach and go through several MMC activities. During the housekeeping waves the 192 
pyloric sphincter opens up and allows sweeping of these materials [9]. Whether a 193 
single unit is retained or lost in gastric emptying is determined by chance and 194 
therefore the high variability in gastric residence time is a drawback for 195 
gastroretentive single unit systems. Multiple unit systems can overcome this. They 196 
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may be evacuated as a linear profile or as a bolus at the end of the digestion [10], 197 
whereas the single unit systems would be evacuated at the end of digestion or 198 
during phase III of IMMC. In this way, multiple unit systems have more reliable 199 
gastric residence patterns because they do not suffer from the “all or none concept” 200 
[9]. 201 
The density of a gastroretentive system affects its location in the stomach. When a 202 
system has a density lower than that of the gastric content (1.004g/ml), they float at 203 
the top and denser systems sink to the bottom. Both situations may keep the 204 
formulation in the stomach and avoid the pylorus [10]. This is shown in figure 4. In a 205 
study by Timmermans and Andre,1994) [11] that examined the effect of floating 206 
properties on gastric residence time, it was found that floating units remained 207 
buoyant and were less likely to be expelled from the stomach compared to the non-208 
floating units. These lay close to the antrum and the pylorus and were expelled into 209 
the intestine by the peristaltic waves. The dosage form parameters that affect its 210 
gastric residence are summarised in Table 4. 211 
 212 
 3.0 Gastroretentive strategies 213 
Gastroretentive strategies are suitable for compounds that are: 214 
 primarily absorbed from the stomach or upper gastrointestinal tract, for 215 
example, metronidazole 216 
 drugs that act locally in the stomach, for example misoprostol, antacids and 217 
antibiotics 218 
 drugs poorly soluble in alkaline pH, for example, diazepam, verapamil 219 
hydrochloride. Gastric retention prevents solubility being the rate limiting step 220 
 drugs with a narrow absorption window in the stomach or upper intestine, for 221 
example, levodopa, furosemide and simvastatin [12]. 222 
 rapidly absorbed drugs, for example, amoxicillin 223 
 drugs that degrade in the colon, for example, captopril [8]. 224 
Unsuitable candidates include drugs that are absorbed equally throughout the 225 
gastrointestinal tract, such as isosorbide dinitrate, drugs that are unstable in stomach 226 
pH, and drugs that irritate stomach mucosa [3]. Various strategies have been used to 227 
prolong gastric residence. These are summarised in the following sections. These 228 
strategies still depend on the presence of gastric fluid for the system to work 229 
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effectively. This translates into patient instructions to take the dosage form with food 230 
and water. In order for a dosage form to be successfully gastroretentive, it must be 231 
able to withstand the stomach waves and, equally important, it must be easily 232 
removed from the stomach once the drug release is complete [8]. 233 
3.1 Floating drug delivery systems 234 
Floating gastroretentive systems, as the name implies, remain afloat over the gastric 235 
contents because of their buoyancy and low bulk density. This allows these systems 236 
to remain in the stomach for a prolonged period of time, while the drug is being 237 
released at a desired rate [5]. Eventually they are eliminated and emptied from the 238 
stomach. There are several methods used to create a floating delivery system and 239 
they can be broadly classified in to two categories: effervescent and non-240 
effervescent formulations. Floating dosage forms may be designed as a single unit 241 
or a multiple unit.  242 
3.1.1 Effervescent systems (gas generating) 243 
Effervescent systems contain a floatation chamber, which is filled with an inert gas, 244 
air or vacuum [5, 13]. This chamber is created within the formulation when it is in 245 
contact with gastric fluid or warms up to body temperature, depending on the system 246 
used. Gas can be produced by an effervescent chemical reaction involving 247 
carbonates or bicarbonates with an acid. The acid can be from the surrounding 248 
gastric environment or can be included in the formulation as citric acid or tartaric acid 249 
[10]. This reaction generates carbon dioxide gas and fills the chamber with gas, 250 
keeping the delivery system afloat. Surrounding the gas chamber is a matrix of 251 
swellable hydrophilic polymer, which expands from the collapsed form to the 252 
expanded form as the chamber is filled with gas [5]. This matrix is insoluble and 253 
permeable to water but not carbon dioxide. Substances that have been used include 254 
chitosan and methocel. The effervescent substances may also be entrapped within 255 
the polymer matrix and the produced gas would trap bubbles in a swollen matrix [10]. 256 
Figure 5 illustrates this process.  257 
In another technique, a volatile organic solvent such as ether or cyclopentane is 258 
included in the floatation chamber. This solvent evaporates at body temperature to 259 
fill the chamber and produce the same floating effect [5, 10]. In vitro the lag time until 260 
the unit floats is less than one minute and it remains afloat for 8 to 10 hours. In vivo 261 
studies in fasted dogs showed a mean gastric residence of up to 4 hours [10]. 262 
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The effervescent systems can be formulated as a single unit system or a multiple 263 
unit system. A single unit system, such as a tablet or capsule, may be a one layer 264 
system that has the effervescent components in the hydrophilic polymer matrix and 265 
carbon dioxide bubbles are trapped in this swollen matrix. It may also be formulated 266 
as two or more layers, which are formulated separately, and further refinements 267 
involve coating with a semipermeable membrane [10]. Multiple unit systems avoid 268 
the ‘all or nothing’ emptying process.  269 
In a study by Hu et al (2011) [14), sustained release floating tablets were prepared to 270 
deliver dextramethorphan via gas generation. The tablets were prepared by a wet 271 
granulation technique with HPMC, sodium bicarbonate as the gas generating agent, 272 
hexadecanol as a floatation assistant, lactose and ethylcellulose solutions the 273 
binding agent. The tablets took three minutes to float in vitro and floatation lasted 274 
over 24 hours. By 12 hours, over 85% of the drug was released. A pharmacokinetic 275 
study in humans comparing the floating tablets to a regular sustained release tablet 276 
showed increased area under the curve (AUC) in concentration time graph and a 277 
prolonged Tmax. In a study by Goole et al. (2008) [15], sustained release floating mini 278 
tablets for levodopa that were made using sodium bicarbonate, calcium carbonate 279 
and tartaric acid as gas generators. Gastric residence time was evaluated in humans 280 
with gamma scintigraphy and compared to marketed Prolopa®. The results showed 281 
gastric retention of four hours and more constant drug pharmacokinetics.  282 
In a study by Tadros (2009)[16], ciprofloxacin was prepared in an effervescent 283 
floating tablet using sodium or calcium carbonate to generate gas. The matrix was 284 
made of hyrdoxypropylmethylcellulose K15M. In vitro testing showed a 16 second 285 
lag time till floatation, which lasted longer than 12 hours suggesting that that 286 
generated gas was successfully entrapped and kept the system floating. In vivo 287 
studies in a human volunteer showed a lag time of 78 seconds, floatation for three 288 
hours in one location then further retention of another three hours in a lower location 289 
in the stomach. The mean gastric retention was 5.5 hours. This formulation showed 290 
promising results for the gastroretentive delivery of ciprofloxacxin. 291 
 292 
3.1.2 Non effervescent (hydrodynamically balanced systems) 293 
 Hydrodynamically balanced systems are single unit dosage forms composed of a 294 
hydrophilic polymer matrix that contains the drugs. The polymer swells when it 295 
becomes hydrated and forms a lightweight gel. Usually they are administered as 296 
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gelatin capsules. In the gastric contents, the gelatin shell erodes away and dissolves 297 
in the gastric fluid. The polymer is now exposed to the gastric fluid and starts to swell 298 
at the surface, therefore forming a gel barrier surrounding the capsule dosage form. 299 
This hydrated outermost layer gives buoyancy and keeps the capsule afloat. It also 300 
keeps the capsule shape together to prevent it from disintegrating and controls the 301 
rate of drug release. Continuous erosion of the surface allows water to penetrate in 302 
to the inner layers thus maintaining surface hydration and buoyancy. Figure 6 303 
illustrates the process.  304 
Gel forming polymers that can be used for such formulations include 305 
hydroxypropylmethylcellulose (HPMC) [17], hydroxyethylcellulose (HEC), 306 
hydroxypropyl cellulose (HPC) sodium carboxymethylcellulose, agar and alginic acid. 307 
Ali et al (2007)[18] produced a hydrodynamically balanced system for metformin. 308 
HPMC and EC were used as polymers and the optimized formulation was tested in 309 
rabbits. In vitro buoyancy studies showed floatation up to 12 hours and gamma 310 
scintigraphy showed the formulation was buoyant for five hours in rabbits. The AUC 311 
was increased by 136% compared to the immediate release formulation and the 312 
release was prolonged with cmax being at 7 hours in the gastroretentive formulation 313 
and 3 hours in the immediate release formulation. The formulation was able to 314 
successfully remain in the stomach for a prolonged period of time and constantly 315 
deliver metformin to its site of absorption, the proximal small intestine.  316 
3.1.3 Raft forming systems 317 
Raft systems are gel forming solutions that swell and form a viscous cohesive gel 318 
which floats on the top of gastric fluid. The dosage form includes an alginate solution 319 
such as sodium alginate that contains carbonates or bicarbonates. When in contact 320 
with the gastric environment, the alginate solution forms the viscous gel with 321 
entrapped carbon dioxide bubbles. This enables the system to float. Figure 7 shows 322 
how these systems appear in the stomach. This floating delivery design is very 323 
useful for gastroesophageal reflux because the raft produced prevents gastric 324 
contents from seeping back to the oesophagus and cause irritation. A well-known 325 
and widely used product is Gaviscon (GlaxoSmithKline) [3]. Raft systems can also 326 
be used for antibiotics, for example, clarithromycin for H.Pylori eradication [19]. This 327 
formulation resulted in greater in vivo H. Pylori eradication as compared to the 328 
solution formulation. 329 
 330 
11  
 
3.1.4 Low Density Systems 331 
Hollow microspheres are multiple unit dosage form with low density (<1g/cm3) and 332 
immediate buoyancy. They are also called microcapsules or microballoons because 333 
of the low density core in their structure. Gastric contents have a density close to 334 
water, 1.004g/cm3, and particles less dense than that float [10,20]. Other examples 335 
of low density systems are microparticles, hollow beads, emulgel beads and floating 336 
pellets [3]. Microspheres can be between 1 and 1000um in size, commercial 337 
microspheres are between 3 and 800 µm [21, 8] and ideally are smaller than 200 µm 338 
[10]. The core makes up 10 to 90% of the microparticle weight [8]. Polymers that can 339 
be used to formulate them include albumin, gelatin, starch, polymethyacrylate, 340 
polyacrylamine and polyalklcyanoacrylate. These microshperes are usually a free 341 
flowing powder with very good in vitro floatability and have a high loading capacity [5]. 342 
Currently, floating microspheres are considered to be the most promising buoyant 343 
systems because they combine the advantages of multiple unit systems and have 344 
good floating properties. Like all other floating systems, however, they still depend 345 
on the presence of enough liquid in the stomach, which requires frequent drinking 346 
[10].  347 
In a study by Miyazaki et al (2007)[22], theophylline was incorporated into floating 348 
gastroretentive microspheres. The floating formulation showed in vitro floatation of 5 349 
hours. An in vivo assessment was carried out in Beagle dogs and showed highest 350 
AUC for the floating formulations. The floating formulation improved gastric retention 351 
and oral bioavailability. Joseph et al (2002) [23], conducted a study for piroxicam 352 
loaded hollow polycarbonate microspheres via the solvent evaporation technique. 353 
The resultant floating microspheres had entrapment efficiencies over 95%, and over 354 
90% of drug was released at 8 hours in vitro. In vivo evaluation in rabbits showed 355 
multiple peaking, suggesting enterohepatic recirculation and the bioavailability was 356 
1.4 times the free drug control. The data showed that the formulation was successful 357 
in retaining the drug to provide sustained drug delivery and enhanced bioavailability.  358 
3.2 Modified Shape Systems 359 
Modified shape systems are composed of biodegradable polymers folded in a 360 
compressed form, which expand to form a three dimensional geometric shape in the 361 
stomach. This dosage form withstands gastric emptying because the expanded form 362 
is bigger than the pyloric sphincter and is small enough to swallow in the folded form. 363 
This folded form is incorporated in a capsule carrier, which dissolves in the stomach. 364 
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Expansion occurs via osmosis and the shape unfolds due to mechanical shape 365 
memory [5]. The device is eliminated when it reduces in volume and rigidity due to 366 
depletion of drug and expanding agent. The polymer also erodes and these prevent 367 
gastric obstruction or accumulation of repeated doses [10]. The different geometric 368 
forms are shown in figure 8. 369 
Despite the interesting properties and mechanism of action of this dosage form, 370 
expandable systems have important drawbacks. The mechanical shape-memory is 371 
short lived and these systems are difficult to industrialise and may not be cost-372 
effective. Storage of easily hydrolysable, biodegradable polymers is challenging. It is 373 
important for such systems to have reproducible ‘collapse time’ so that it does not 374 
cause obstruction or gastropathy [10].  375 
 376 
3.3 Bioadhesive systems 377 
Bioadhesive or mucoadhesive systems are designed with materials that adhere to 378 
the mucosal membranes. These systems resist emptying and therefore have 379 
prolonged gastric residence. For example, microspheres, microparticles [24]or 380 
liposomes can be coated with bioadhesive material. Bioadhesive polymers adhere to 381 
either the mucus lining or the biological membranes. Polymers include chitosan, 382 
carbopol, carboxymethyl chitin and carboxymethyl chitosan [3]. Several mechanisms 383 
have been proposed for mucoadhesion. The electrostatic theory proposes that 384 
adhesion is via attractive electrostatic forces between the glycoprotein mucin 385 
network and the polymer. The adsorption theory proposes that adhesion is due to 386 
Van der Waals and hydrogen bonding. The wetting theory is based on the polymers’ 387 
ability to spread and the diffusion theory is based on the physical entanglement of 388 
mucin strands with the flexible polymer chains, or an interpenetration of the mucin 389 
strands in the porous polymer structure [10].  390 
Formulation and clinical use issues of these systems include unpredictable 391 
adherence because the mucus layers are in a constant state of renewal. In addition, 392 
the gastric content is highly hydrated which reduces the binding property and it is 393 
difficult to target these dosage forms because they may adhere to membranes or 394 
mucus in other locations. This raises concerns about oesophageal binding, which 395 
also presents a challenge [5]. Figure 9 illustrates gastroretention of bio-adhesive 396 
microspheres. Liu et al (2004) [25] compared amoxicillin powder, amoxicillin 397 
entrapped in microspheres and bioadhesive amoxicillin loaded microspheres in 398 
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Helicobacter Pylori eradication. The results showed that mucoadhesion had 399 
prolonged gastric residence and greater amoxicillin levels leading to better therapy 400 
than the regular microspheres. Rajinikanth et al (2008) [19] formulated floating 401 
bioadehesive microspheres containing clarithromycin for H. Pylori eradication. The 402 
matrix polymer was ethylcellulose and carbopol P934. The resulting microspheres 403 
showed strong adhesion and buoyancy. In vivo studies in Mongolian gerbils showed 404 
that significantly less clarithromycin was needed for H. Pylori eradication using the 405 
designed formulation compared to the regular suspension. The formulation was also 406 
successful in stabilising clarithromycin, which is known for its acidic instability. 407 
3.4 Swelling and Expanding Systems 408 
Swelling and expanding systems are composed of super-porous hydrogels that swell 409 
to a large size, with a swelling ratio of approximately 100 times or more. Swelling 410 
occurs through rapid water uptake via capillary action through the pores, which are 411 
usually greater than 100 µm in size. In addition, they swell to equilibrium size in less 412 
than one minute. These properties set this system apart from conventional ones, 413 
which have pore sizes between 10nm and 10µm and have slow swelling that takes 414 
several hours to reach equilibrium [10]. Figure 10 illustrates swelling and expanding 415 
systems. The superporous hydrogels are also intended to have sufficient mechanical 416 
strength to withstand gastric contraction pressure. In a study by Gupta and 417 
Shivakumar (2010) [26], rosiglitazone was formulated in a swelling super-porous 418 
hydrogel. The drug is extensively absorbed from the stomach and therefore could 419 
benefit from gastroretention in anti-diabetic therapy. Chitosan and polyvinyl alcohol 420 
were used as a polymer network. The hydrogels were sensitive to pH and showed 421 
reversible swelling and de-swelling but still retaining its mechanical stability. 422 
Chitosan which acted as a cross linker, determined the swelling characteristics and 423 
polyvinyl alcohol gave the formulation the required mechanical strength. In vitro drug 424 
release was sustained for 6 hours and this formulation was found to be successful 425 
for rosiglitazone delivery in gastric pH. In another study by Chava and Patel (2011) 426 
[27], a super-porous hydrogel was made to deliver ranitidine hydrochloride. The 427 
system was made with hydroxypropylmethyl cellulose and had interconnected pores 428 
and channels. In vitro, the system remained afloat and continued to deliver ranitidine 429 
for 17 hours showing a Korsmeyer-Peppas release profile. The formulation proved to 430 
be a successful system for gastroretentive delivery of ranitidine. Others have used 431 
14  
 
gellan gum, sodium alginate, pectin and xanthan gum polymers to prepare size 432 
expanding gastroretentive systems [28]. 433 
3.5 Magnetic systems 434 
Magnetic systems contain a small internal magnet and an external magnet placed 435 
externally on the abdomen and above the stomach to attract and hold the dosage 436 
form in place. This can be accomplished with the addition of ferrite [10]. Although 437 
these systems works very well in these trials and in theory, in practice the external 438 
magnet must be positioned with a degree of accuracy that may compromise patient 439 
compliance [10] or lead to sub-therapeutic treatment. 440 
High density system 441 
High density systems are made up of pellets with a density higher than gastric fluid 442 
density. When the patient is in the upright position, the system sinks to the bottom, 443 
withstands the peristaltic gastric waves and avoids the pylorus. It has been found 444 
that a density close to 2.5g/cm3 is needed for sufficient residence time and 445 
excipients used include barium sulphate, zinc oxide, iron and titanium dioxide. 446 
Although these systems have shown successful gastric retention in animal models, 447 
they are not very effective in humans and there are no marketed systems utilising 448 
this strategy [10].  449 
 450 
Gastroretentive formulations can be designed as single unit systems or multiple unit 451 
dosage forms. Single unit systems are inefficient in prolonging the gastric retention 452 
time of drugs due to their all-or-nothing emptying process which may lead to inter-453 
subject variability in drug bioavailability. In addition, their use maybe associated with 454 
local irritation due to high concentration of the drug in particular site of the GIT. On 455 
the other hand, multiple unit dosage forms including microspheres distribute 456 
uniformly in the GIT, and therefore overcome the gastric emptying problems, provide 457 
consistent drug release in the GIT and avoid local irritation of the drug [29].  458 
Processing techniques for formulation of multiple unit microspheres gastroretentive 459 
dosage forms have been extensively developed. They are shown below. 460 
 461 
4.0 Microspheres production methods 462 
Gastroretentive microspheres can be prepared by three main techniques: solvent 463 
evaporation, spray drying and coacervation. Other methods are modifications of 464 
these three basic methods [30]. A successful formulation of microspheres needs to (i) 465 
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have sufficient drug loading, (ii) be chemically and physically stable for a clinically 466 
acceptable shelf life, (iii) have controlled particle size, and (iv) have controlled drug 467 
release to achieve therapeutic effect and side effect minimisation ( [31]. 468 
4.1 Solvent evaporation 469 
Solvent evaporation for the preparation of low density systems has achieved 470 
tremendous popularity and floating microparticles were the primary dosage form of 471 
choice [5].This is an emulsion based method and does not involve highly elevated 472 
temperatures like spray draying and is therefore suitable for temperature sensitive 473 
compounds. It also does not involve phase separating agents. This means that the 474 
resulting microspheres do not have residual solvents, as is the case with phase 475 
separation and coacervation methods [6]. There are different ways to make 476 
microspheres via solvent evaporation and the choice of method depends on the 477 
drug’s hydro- and lipophilicity [32, 33]. Lipophilic drugs are incorporated with oil-in-478 
water (o/w), which is the simplest and most frequently used method [32]. Hydrophilic 479 
drugs formulated in this way would not be appropriate because the drug may not 480 
dissolve in the lipophilic solvent and also diffuse through to the hydrophilic 481 
continuous phase. These limitations for hydrophilic drugs can therefore be overcome 482 
with the addition of a co-solvent to increase drug solubility, drug addition as a 483 
dispersion of solid powder, using a system composed of a lipophilic solvent, such as 484 
mineral oil, and therefore form an oil in oil emulsion or the formation of a double 485 
emulsion with water-in-oil-in-water [32]. 486 
Solvent evaporation involves four steps to microsphere production. These are (i) 487 
dispersion or dissolution of the drug in an organic solvent that contains the matrix 488 
forming material, (ii) emulsification of organic phase in a lipophilic phase, (ii) solvent 489 
removal and finally, (iv) harvesting and microsphere drying [30, 31]. These steps are 490 
illustrated in figure 11. Polymers and solvents commonly used with this method are 491 
shown in Table 5.  Emulsion formation in the second step is the primary determinant 492 
of final product particle size and particle size distribution. Microsphere size 493 
determines the rate of drug release, drug encapsulation efficiency and in vivo fate [6]. 494 
Factors that improve the encapsulation efficiency are (i) low polymer solubility in 495 
organic solvent, (ii) high solubility of organic solvent in water, (iii) high concentration 496 
of polymer, (iv) low dispersed phase to continuous phase ratio and (v) fast solvent 497 
removal rate [21]. Other factors that affect microsphere properties are summarised in 498 
table 6. 499 
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4.2 Spray drying 500 
Spray drying is a process that involves transforming an emulsion, suspension, 501 
dispersion or liquid to a dry state by atomization followed by drying [34 35]. The spray 502 
process involves three steps: (1) atomization or droplet formation (2) solvent 503 
evaporation and (3) particle collection. However, these steps are continuous and are 504 
only described in different sections to make explanation easier. In brief, a stream of 505 
liquid is atomized to fine droplets, and then dried in a chamber to give solid particles. 506 
This is then collected with a suitable dry collector [36]. Spray drying is less 507 
dependent on the hydrophilicity or solubility of a compound or polymer and can be a 508 
good choice for hydrophilic drugs that leech out in solvent evaporation techniques. 509 
Parameters that affect the final product characteristics include inlet air temperature, 510 
liquid feeding rate, rate of atomized airflow and particle residence time. These 511 
variables affect the particle size, size distribution, particle morphology and bulk 512 
density [34]. Figure 12 illustrates how a spray dryer works.  513 
4.2.1 Atomization: 514 
In the atomization process, the liquid is reduced to fine droplets as it passes through 515 
the atomizer spray nozzle. This can be achieved with centrifugal, electronic or 516 
ultrasound pressure. Different types of atomizers are designed to produce different 517 
particle size ranges, for example, the ultrasonic neubilizer produces particles in the 1 518 
to 10 µm range and hydraulic nozzle atomizer produces particles of 100 to 400µm 519 
size range. Other factors that influence droplet size are viscosity, density and surface 520 
tension in the liquid [36,34]. 521 
2.3 Solvent evaporation  522 
The liquid droplets are carried by an inert gas through the drying chamber and they 523 
form solid particles. Usually drying chambers work with electric heaters. 524 
Homogenous particles result from laminar gas flow with uniform heating (Heng et al., 525 
2011). Solvent evaporation is fast and by simultaneous heat and mass transfer. The 526 
drying rate is affected by the difference in temperature between the atomized 527 
droplets and the air in the spray drying chamber. In addition, the scale of the batch or 528 
rate of atomization can affect drying rate. This generally takes between a few 529 
seconds to a minute [34]. 530 
2.3.3 Particle collection 531 
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The most common method of solid particle collection and separation is the cyclone. 532 
This works with a rotating air stream, which generates a centrifugal force on the 533 
particles. This force pushes the particles against the walls of the collection chamber. 534 
Another method is via bag filtration, which uses fabric to separate the particles from 535 
the exhaust air. Electrostatic precipitators are also an option; however, they are not 536 
widely used due to their high cost.  However, they have the potential to collect 537 
particles smaller than 2µm and down to 50nm [36].  538 
 539 
4.3 Phase separation or coacervation 540 
Phase separation, also called coacervation, is process where a system composed of 541 
colloidal particles dispersed in a medium separates in to two different phases, a 542 
colloid rich and colloid poor phase. This separation process can be brought upon 543 
with a coacervating agent to produce coacervate droplets, which can be solidified 544 
with a hardening agent to produce the microspheres [37].  545 
In detail, coacervation involves several steps. Firstly, the polymer that will provide 546 
suitable coating or matrix characteristics is dissolved in a suitable solvent. In the 547 
case of a core that requires coating, it may be mixed at this stage with the polymer 548 
solution. The solvent should not dissolve this core. Coacervation is brought upon by 549 
various techniques, for example, the addition of a non-solvent for the polymer, salt 550 
addition or pH change. This causes the polymer to concentrate in a new separate 551 
phase, the ‘coacervate’, and polymer droplets form with stirring. Most of the solvent 552 
initially used to dissolve the polymer is now the polymer-poor phase. The solvent is 553 
removed, by evaporation for example, and the system is further desolvated to 554 
harden the formed polymer particles. This may be by solvent evaporation or other 555 
methods such as thermal desolvation or crosslinking.  Finally the microparticles or 556 
microspheres are collected and may be rinsed to remove unwanted solvents or 557 
excipients [38, 39].  558 
Another variation on this process is emulsion-coacervation. This process uses an oil-559 
in-water emulsion of an organic phase that contains the drug in an aqueous phase 560 
that has the polymer and a stabilising agent. Mechanical stirring or ultrasound aids 561 
the emulsification. Coacervation is brought on with electrolytes, also called salting-562 
out, or addition of a water miscible non-solvent or dehydrating agent [40]. This is the 563 
critical step of microsphere production and the polymer precipitates from the 564 
continuous phase to form a film on the emulsion droplets, which act as a template for 565 
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microsphere formation. Coacervation works through polymer desolvation. While the 566 
polymer is dissolved in water, the water molecules solvate and surround its 567 
functional groups through hydrogen bonding and van der Waals forces. When a 568 
coacervating agent is added, water solvation of the polymer decreases and the 569 
polymer concentrates in the coacervate phase. There is greater attraction among the 570 
polymer chains via secondary valent bonds and non-covalent weak crosslinks and 571 
the polymer forms a thin entangled network film as a shell around the emulsion 572 
droplets [41]. Finally, a crosslinking step produces rigid hollow core spheres. This 573 
can be done with addition of a crosslinking agent, or changing pH or temperature 574 
[40]. Solvent removal, by evaporation for example, leaves the microspheres with 575 
nothing to keep them suspended. It may therefore be necessary to provide another 576 
liquid such as liquid paraffin or water, which does not evaporate appreciably, to 577 
suspend the particles. The microspheres are collected and rinsed to remove solvent 578 
and excipients [38].  579 
 580 
 Microsphere Characterisation  581 
Microparticles are characterised by their micromeritic properties such as particle size, 582 
tapped density, bulk density, compressibility and angle of repose. Scanning electron 583 
microscopy can be used to examine microsphere internal structure to confirm the 584 
hollow core nature [8, 42]. In addition, they are characterised on their specific gravity, 585 
content uniformity and drug release [9].  586 
Particle size can be measured with laser diffraction particle size analysers and larger 587 
particles can also be examined under the light microscope. The mean particle size 588 
can be obtained from measurement of 200 to 300 particles using a calibrated 589 
micrometer [8]. Particle sizes and their distribution can also be obtained from sieving. 590 
This separates the microspheres into different size fractions using a mechanical 591 
shaker.  592 
Drug release studies can be dissolution studies in USP dissolution apparatus ([;[ 43]. 593 
Samples are withdrawn at specified times and fresh medium is replaced. Floating 594 
dosage forms may not remain afloat for the dissolution test and therefore must be 595 
allowed to sink to the bottom first. The USP states “a small, loose piece of non-596 
reactive material such as not more than a few turns of a wire helix may be attached 597 
to the dosage units that would otherwise float.” However, standard dissolution 598 
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methods are poor predictors of in vitro performance. In addition, in vitro results 599 
correlate poorly with in vivo results. Various ways to overcome these limitations have 600 
been suggested. Burnes et al (1995) [44] modified the standard method so that the 601 
paddle rotates at the surface. The results were reproducible and dissolution profiles 602 
were unaltered with rotation speed change, pH change and bile acid concentration 603 
increase. In this regard, this validated method is superior to the BP method. Pillay 604 
and Fasihi (1998) [45] proposed submerging the floating system under a mesh. The 605 
results showed increased drug release and consistent release profiles. 606 
The specific gravity can be measured by the displacement method using benzene as 607 
a displacing medium [46]. Microspheres for gastroretentive purposes are designed to 608 
float. In vitro floatability studies can be done using a USP II dissolution apparatus. 609 
The medium is 900 ml of simulated gastric fluid and contains 0.1N hydrochloric acid, 610 
sodium chloride and 0.02% tween 80. This makes the medium pH 1.2 and gives it a 611 
surface tension resembling human gastric juice, which is between 35 to 50 mN/m2 [8]. 612 
The temperature is maintained at 37oC ± 0.5oC and stirred at 100rpm. The floatability 613 
is measured as percent buoyancy by noting the proportions of floating and settled 614 
microspheres [8]. The formula is given below: 615 
Buoyancy percent = mass of floating spheres / (mass of floating spheres + mass of 616 
settled spheres) x100   617 
A microsphere floats when the total force is positive and in the upward direction 618 
(9Arora et al., 2005). The forces acting on a sphere are the buoyancy (Fb) and the 619 
gravitational force (Fg). The sum of these forces gives the net force and this can be 620 
written as given by Timmermans and Andre: 621 
F = Fb - Fg  (1) 622 
Fluid density, solid object density, weight and volume of the test object also affect 623 
the net force and the relationship is given by equation 2, as described by 624 
Timmermans and Andre and further developed by Li et al, 2008 [38]. 625 
F = (fluid density – solid density) x g x solid volume (2) 626 
These equations are useful in microsphere characterisation and in successful design 627 
of floating gastroretentive formulations. It can be seen for example, that the solid 628 
density and volume of the object are very important parameters for overall floating 629 
force. During buoyancy measurement, the spheres swell and increase in volume and 630 
the density increases due to water uptake. The solid density and solid volume 631 
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parameters therefore increase in equation 2, leading to a net upward force that 632 
keeps the formulation afloat [9]. Although the USP and BP methods give important 633 
information on floatability, the results do not correlate well with in vivo performance.  634 
Floating studies may also be conducted in vivo in animals and humans. They are 635 
carried out under fed and fasted conditions using floating and non-floating forms to 636 
act as test and control. The Tmax, Cmax and AUC are obtained from graphical data of 637 
drug blood levels after administration of dosage form.  638 
Visualisation of floating dosage forms is important for evaluating gastrointestinal 639 
retention because the pharmacokinetic data is an indirect assessment of gastric 640 
retention. This can be done by X-ray or gamma scintigraphy. Microparticles loaded 641 
with radio-opaque materials, such as barium sulphate, can be followed through by X-642 
ray photographs. Gamma scintigraphy can also be used to monitor transit of labelled 643 
floating microspheres. This is done by including a gamma-emitting radionuclide in 644 
the formulation and visualisation is external with a gamma-camera or scintiscanner 645 
that capture emitted gamma waves to observe the location of the formulation in the 646 
gastrointestinal tract [3].  647 
 648 
 649 
Application and case studies of floating microsphere 650 
Floating drug delivery systems have important applications for drugs with poor 651 
bioavailability due to a narrow absorption window. They are particularly 652 
advantageous for drugs mostly absorbed from the stomach or upper intestine and for 653 
drugs that have poor solubility and limited absorption due to short gastric residence 654 
[9]. 655 
Site specific drug delivery is an advantage in floating drug delivery because most of 656 
the drug is released in the stomach and duodenum. Conditions such as stomach 657 
ulcers infected with Helicobacter Pylori are more successfully eradicated with 658 
targeted delivery than regular therapy. H. Pylori infections have been associated with 659 
short and long term morbidity including reduced gastric motility, reduced acid 660 
secretion, increased stomach membrane permeability, dyspepsia, gastritis, gastric 661 
cancer and mucosa-associated lymphoid tissue (MALT) lymphomas [10]. Standard 662 
and best practice therapy for H. Pylori eradication is 1g amoxicillin twice daily for one 663 
week along with 500 mg clarithromycin and 20 mg omeprazole, also taken twice 664 
daily (NZGG, 2004). This triple treatment requires good patient compliance for 665 
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success and missed doses lead to treatment failure. Many studies have been 666 
conducted to assess the success of gastro-retentive strategies in improving H. Pylori 667 
eradication.  Liu et la (2004) [25] formulated bioadhesive microspheres as a floating 668 
gastroretentive dosage form for the delivery of amoxicillin. In vitro studies showed 669 
that amoxicillin release was faster in acidic pH than in slightly basic pH. Amoxicillin is 670 
known to be unstable in acidic pH and given that the dosage form increase gastric 671 
residence time, this factor had significant importance. It was found that microspheres 672 
entrapment was useful to keep it stable.    673 
In vitro and in vivo mucoadhesive tests showed that the mucoadhesive microspheres 674 
have certainly adhered more strongly to gastric mucosa and were retained for longer 675 
periods in the stomach. Rats infected with H. Pylori and treated with plain amoxicillin 676 
powder, amoxicillin microspheres and mucoadhesive amoxicillin microspheres 677 
showed interesting results. Amoxicillin concentrations were directly measured from 678 
gastric juice and mucoadhesive formulations showed greater concentrations 679 
(Concentration ratios of 1.38, 1.74 and 1.15 at 1, 2 and 3 hours respectively). This 680 
significantly greater antibiotic concentration at the target delivery site strongly 681 
suggests that such formulations can have enhanced efficacy. The results also 682 
showed that the increase in amoxicillin dose, which increases H. Pylori eradication, 683 
was more pronounced in the mucoadhesive formulation. The authors concluded that 684 
this preliminary study has significant finding and similar studies need to be 685 
conducted in larger animals to confirm the results. 686 
Floating drug delivery systems have controlled release applications. They remain in 687 
the stomach for a prolonged period of time and the drug release rate can be 688 
controlled. Regular controlled release formulations suffer from variable and short 689 
gastric residence and cannot deliver drugs with narrow absorption windows 690 
successfully. In a study by Dong et al (2010) [47] sustained release microspheres 691 
were formulated for rosiglitazone, a drug which is used to increase sensitivity to 692 
insulin in patients with type 2 diabetes and important in its treatment. Currently, it is 693 
used as adjuvant therapy in patient that cannot get sufficient insulin sensitivity from 694 
first line treatment [48]. Rosiglitazone has a narrow absorption window in the 695 
stomach and duodenum benefits from gastroretentive sustained delivery. 696 
Ethylcellulose and octadecyl alcohol were used as carriers and over 90% of the 697 
microspheres floated in vitro for 12 hours. The pharmacokinetic studies conducted 698 
on human volunteers showed that the formulation had a superior profile to 699 
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commercial tablets because peak plasma concentration was decreased and 700 
rosiglitazone concentration remained in the plasma for a longer time (T1/2 increased 701 
from 4 to 7 hours). At the same time, the area under the curve was comparable in 702 
the commercial and developed formulations, indicating that the bioavailability was 703 
not reduced. The study concluded that the developed once daily rosiglitazone 704 
sustained release microspheres formulation is good alternative to conventional 705 
tablets. 706 
Marketed systems 707 
The last thirty years of intensive gastroretentive formulation research has led to the 708 
marketing of a large number of products. In 1999, literature cites the marketing of 709 
five products, in 2007 eight products are cited (Kumar and Philip, 2007)[3] and in 710 
2011, 24 gastroretentive products are in the market [5]. The popularity of 711 
gastroretentive strategies is rapidly growing day by aday and some formulations are 712 
described below. 713 
Madopar LP® is a marketed formulation using a hydrodynamically balanced system 714 
to deliver 100mg of levodopa and 25mg benserazide. It was marketed by Roche in 715 
the 1980s [10] and is commercially available in Europe but not the US [46]. This is a 716 
controlled release formulation that is made up of a gelatin capsule that floats on 717 
gastric fluid. This capsule shell dissolves and the mucus body is formed. The drug 718 
diffuses through the hydrated outer layers of the matrix as it slowly dissipates [46]. 719 
Valrelease® is another marketed gastroretentive formulation that contains 15mg 720 
diazepam. The system is a hydrodynamically balanced system made of a floating 721 
capsule and is marketed by Hoffmann-La Roche [3]. Diazepam is a good drug 722 
candidate for gastroretentive strategies because its pKa of 3.4 makes its absorption 723 
favourable in the stomach and not the small intestine.  The HBS allows maximal 724 
dissolution of diazepam in an environment where it has maximal solubility and 725 
absorption. The pharmacokinetic data illustrates the benefit of this gastroretentive 726 
formulation, with once daily dosing of Valrelease being equivalent to 3 times daily 727 
dosing of regular 5mg Valium® tablets [46]. 728 
Topalkan® and Almagate Flot-Coat® are two other gastroretentive formulations that 729 
deliver antacids locally to the stomach by forming a floating raft on the stomach 730 
contents [3]. Toplakan® is a third generation aluminium-magnesium antacid that has 731 
greater availability of alginic acid in the formula. This property, in addition to its 732 
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antacid property, sets it apart from other formulations. Almagate Flot-Coat® is also a 733 
novel formulation because it has a higher antacid potency than regular formulations 734 
and provides relief over a prolonged period of time owing to its gastroretentive 735 
properties. Unlike regular antacid formulations that are rapidly neutralised in the 736 
stomach or sediment to the fundus and are eliminated, these formulations provide 737 
greater antipeptic and stomach membrane protective benefits. 738 
Conviron® is a ferrous sulphate formulation based on a gel forming floating drug 739 
delivery system marketed by Ranbaxy [3]. Iron suffers from poor oral bioavailability 740 
and need for prolonged treatment to increase iron stores to clinically acceptable 741 
levels. In addition, this has necessitated the use of high doses, which lead to side 742 
effects such as constipation, gastric upset and diarrhoea. A summary of the 743 
marketed gastroretentive formulations is presented in table 7. 744 
 745 
Conclusion 746 
The oral route is a very important and widely used in drug delivery. Gastroretentive 747 
strategies inherently have several advantages in overcoming the variable gastric 748 
residence and targeting to absorptive windows. In effect, gastroretentive strategies 749 
improve oral bioavailability and optimise drug plasma levels leading to enhanced and 750 
predictable therapeutic outcomes. Microspheres are widely used for gastroretention 751 
and have the advantage of being multi-unit. They may be successfully manufactured 752 
via solvent evaporation, spray drying or coacervation. Floating drug delivery has 753 
important applications such as sustained release and drug targeting. The success of 754 
gastroretentive strategies can be seen in the increasing numbers of marketed 755 
products. 756 
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Figure 1: Drug absorption through the absorption window. In (a) a regular dosage form. 935 
There is little absoprtion beyoynd the absorption window (b) a gastroretentive formulation, 936 
where there is continued release above the absoprtion window and constant absorption 937 
thorugh it. 938 
 939 
 940 
 941 
 942 
 943 
 944 
 945 
 946 
29  
 
 947 
 948 
 949 
 950 
 951 
 952 
 953 
 954 
 955 
 956 
 957 
 958 
 959 
Figure 2: Stomach anatomy 960 
 961 
 962 
 963 
 964 
 965 
 966 
 967 
 968 
 969 
 970 
 971 
 972 
 973 
Fundus 
Body  
Pylorus 
Cardia 
Duodenum 
30  
 
 974 
 975 
 976 
 977 
 978 
Figure 3: Simple representation of intergastric motility pattern, showing frequency, intensity 979 
and pattern of contractions. (Talukder and Fassihi, 2004). 980 
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Figure 5: Effervescent floating formulation in the stomach 1015 
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Figure6: hydrodynamically balanced systems 1032 
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Figure 7: Raft forming systems (adapted from Bardonnet et al., 2005) 1057 
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Figure 8: various examples of modified shape systems (Bardonnet et al., 2005; Klausner et 1077 
al., 2003) 1078 
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Figure 9: Bioadhesive microspheres in the stomach have gastroretentive properties (Adebisi 1100 
and Conway 2011) 1101 
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Figure 11a: steps of solvent evaporation technique. 1149 
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 There are three processes occurring during solvent 1166 
evaporation, (i) solvent evaporation at the air liquid interface 1167 
(F1), (ii) solvent diffusion in to the continuous phase (F2) and 1168 
(iii) solvent diffusion inside the drop (F3). 1169 
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Figure 11b: solvent evaporation technique. 1175 
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Figure 12: Spray dryer. 1179 
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Table 1: Examples of drugs with narrow absorption window 1192 
Acyclovir 
Captopril 
Furosemide 
Metformin 
Gabapentin 
Levodopa 
Baclofen 
Ciprofloxacin 
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Table 2: Phases in migrating motor complex (fasting state) (Arora et al., 2005, 
Kumar and Philip 2007) 
 
Phase Description 
I: basal phase Lasts 40-60 minutes 
Rare contractions 
II: preburst 
phase 
Lasts 40-60 minutes 
Intermittent contractions that increase in intensity and frequency 
gradually 
III: burst phase Lasts 4-6 minutes 
Regular and intense contractions 
All undigested material is swept out of the stomach 
Also called the housekeeping wave 
IV: transition 
phase 
Lasts 0 to 5 minutes 
Separates phase III from phase I of the next cycle 
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Table 3: Factors affecting gastric motility (Kumar and Philip 2007, Arora et al, 2005, 
Pawar et al., 2011) 
 
Factor Effect 
Age  Elderly, over 70 years, have significantly slower gastric motility 
Gender  Males have shorter gastric residence (3.4 ± 0.6h) than 
females (4.6 ± 1.2h) regardless of weight, height and body 
surface area  
Posture  Upright position allows floating dosage forms to float 
Floating dosage forms have no advantage in the supine 
position 
Fed state Increased gastric residence time due to presence of food 
Frequent meal intake constantly delays MMC and increases 
gastric residence by over 6 hours 
Meal type Higher caloric content remains increases gastric residnce by 
4-10 hours 
Solids remain longer than liquids 
Starch, cellulose and other fatty acid salts delay the MMC and 
decrease gatric emptying rate 
Disease state Stress conditions increase gastric motility and depression slow 
it down 
Concomitant drug 
administration 
Anticholinergics, opiates, clonidine, lithium, metoclopramide 
and other drugs may slow down gastric motility. Erythromycin 
on the other hand increases gatric motility 
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Table 4: Factors affecting drug gastric residence time (Arora et al., 2005, Pawar et 
al., 2011) 
 
Factor Effect 
Density Gastric residence is a function of buoyancy 
Shape Tetrahedron and ring shaped unfolding expandable systems 
have better retention compared to stick, planar disc or planar 
multilobe or string. 
Size Solids larger than 1-2mm are retained during postprandial 
period  
Solids larger than 13mm remain in the stomach in the 
postpradial period and not expelled until phase III of the MMC 
Single or multiple 
unit 
Multiple unit systems have more predictable residence 
Gastric motility 
phase 
Drug administration during the fasting state encounters strong 
MMC phase III waves that lead to its fast expulsion. 
Administration during the fed state has longer gastric residence.  
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Table 5: Polymers, solvents and stabilisers commonly used in solvent evaporation 1263 
for microsphere formation (Obeidat, 2009, Li et al., 2008, Tran et al., 2011, Freitas et 1264 
al., 2005) 1265 
Abbreviation  Name  Notes  
Polymers  
PLG, PLGA Poly(lactide-co-glycolide), 
Poly(lactic-co-glycolic acid) 
Good biodegradability 
Good biocompatability 
PLA Poly(lactic acid) or polylactide Good biodegradability 
Good biocompatability 
PEG Poly(ethylene glycol) Used as co-polymer 
EC Ethyl cellulose Biodegradable  
Biocompatible  
Low cost 
PHB, PHB-HV Poly-3-hydroxybutyrate 
Poly-3-hydroxybutyrate with 
hydroxyvalerate 
Bacterial storage polyester 
Slower degradation than 
polylactic polymers 
PMMA Polymethyl methacrylate Non-biodegradable  
Biocompatible  
ploysaccharides E.g. chitosan, alginate  
Used at a lower frequency protiens E.g. albumin, collagen, gelatine 
Lipids  E.g. glyceryltripalmitate 
Solvents   
 Chloroform High toxicity  
Low water solubility 
 Dichloromethane  High toxicity (lower than 
chloroform) 
Almost immiscible in water  
 Ethyl acetate  Low toxicity 
Partially water soluble 
 Ethyl formate Low toxicity 
Partially water soluble 
Stabilisers    
PVA Polyvinyl alcohol Non ionic 
Most widely used 
Gives smallest microspheres 
MC Methyl cellulose Non ionic 
 Tween  Non ionic 
 Span Non ionic 
SDS Sodium dodecyl sulphate Anionic  
CTAB  Cetyltrimethyl ammonium 
bromide 
Cationic  
 1266 
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Table 6: Summary of factors affecting microspheres properties prepared via solvent 1269 
evaporation (Li et al., 2008) 1270 
Factor  Microsphere properties  
Size  Surface 
morphology  
Encapsulation 
efficiency  
Higher dispersed 
phase viscosity  
Larger  smoother Increased efficiency  
Higher dispersed 
phase to continuous 
phase volume ratio 
Smaller   Increased 
Larger amount of drug   More porous, 
irregular shape 
Decreased at high 
drug concentrations 
Increased surfactant 
concentration  
Smaller   No effect 
Increased agitation rate Smaller  Smoother  
Increased temperature Smaller  Coarser surface Decreased 
Reduced pressure Smaller Smoother Increased 
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Table 7: A summary of the marketed gastroretentive formulations (Pawar et al., 1288 
2011, Kumar and Philip, 2007, Brahma and Kwon 1999)  1289 
Brand name Drug Formulation  Company 
Zanocin OD Ofloxacin Effervescent floating system Ranbaxy 
Riomet OD Metformin Effervescent floating system Ranbaxy 
Cifran OD Ciprofloxacin  Effervescent floating system Ranbaxy 
Inon Ace Tablets Simethicone  Foam based floating system Sato Pharma 
Gabapentin GR Gabapentin  Acuform technology: uses 
polymer based swelling 
Depomed 
ProQuin XR Ciprofloxacin  Acuform technology: uses 
polymer based swelling 
Depomed 
Glumetza Metformin  Acuform technology: uses 
polymer based swelling 
Depomed 
Metformin GR Metformin  Acuform technology: uses 
polymer based swelling 
Depomed 
Kadiam Morphine 
sulphate  
 Sumitomo 
Pharma 
Prazopress XL Prazosin  Effervescent and swelling 
based system 
Sun Pharma 
Metformin Hcl LP Metformin  Minextab floating®  Galenix 
Cefaclor LP Cefaclor  Minextab floating® Galenix 
Tramadol LP Tramadol  Minextab floating® Galenix 
Cipro XR  Ciprofloxacin + 
betaine 
Erodible matrix system Bayer 
Accordion Pill TM  Expandable film filled in 
capsule (modified shape 
system) 
Intec Pharma 
Baclofen GRS Baclofen  Multilayer floating and 
swelling system 
Sun Pharma 
Coreg CR Carvedilol Osmotic system Glaxosmithkline 
Madopar Levodopa, 
benserzide  
Hydrodynamically balanced 
system, floating capsule 
Roche 
Gaviscon liquid Alginic acid, 
sodium 
bicarbonate 
Floating raft system Reckitt 
Benckiser 
Healthcare 
Valrelease Diazepam Hydrodynamically balanced 
system, floating capsule 
Roche 
Topalkan Aluminium 
magnesium 
antacid 
Floating raft system Pierre Fabre 
Medicament 
Conviron Ferrous 
sulphate 
Colloidal gel forming GDDS Ranbaxy 
Almagate Flat 
Coat 
Antacid  Flaoting raft  
Oflin  Ofloxacin  Gas generating floating 
tablet 
Ranbaxy  
Cytotex Misoprostol  Bilayer floating tablet Pharmacia 
Limited 
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